Skip to main
WGS

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings is a rapidly growing market leader in rare-disease testing lab services, with expertise in whole-exome and whole-genome sequencing. The company has a positive outlook due to its strong focus on pediatric and rare-disease diagnostics and its strategy to advance precision medicine. Despite a recent tough quarterly update and lowered guidance, the company's potential for growth and investment in expanding its sales force and acquisitions keep the analyst positive on the stock, with a "Buy" rating and a lowered price target of $70.

Bears say

GeneDx Holdings is expected to experience a short-term headwind in revenue due to the shift towards genome sequencing, but a new policy put in place by Carelon is likely to increase average selling price by $100 by H2 2027, potentially offsetting the initial impact. The launch of new tests and the rollout of newborn screening could also drive growth in the future, but it will take a few more years for these initiatives to take full effect. However, the recent Q1 miss and lowered guidance for 2026 suggest potential issues with forecasting and guidance, which could negatively impact the company's performance in the long term.

WGS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Strong Buy based on their latest research and market trends.

According to 5 analysts, WGS has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.